drugset / Trial / NCT05317507
Safety of Co-Administered CHI-554 and Alcohol
RandomizedCrossoverQuadruple-blindOther
Summary
This is a Phase 1, randomized, double-blind study to assess the safety, tolerability, and effects of CHI-554 when co-administered with alcohol.
Timeline
- Start
- 2022-05-09
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 50 mg | — |
| Subject | Cannabidiol | Other / unclassified | 100 mg | — |
Indications
No indication recorded.